# Phase 2 Study of TXA127 in Post-ischemic Stroke Patients

> **NCT06135103** · PHASE2 · UNKNOWN · sponsor: **Constant Therapeutics LLC** · enrollment: 50 (estimated)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** talfirastide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06135103
- **Lead sponsor:** Constant Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-26
- **Primary completion:** 2024-12
- **Final completion:** 2025-09
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06135103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06135103, "Phase 2 Study of TXA127 in Post-ischemic Stroke Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06135103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*